Şener Rıfat, Alataş Süleyman Erkan, Güler Ömer Tolga
Department of Gynecology and Obstetrics, Gynecological Oncology Surgery, Konya City Hospital, Konya, Turkey.
Department of Gynecology and Obstetrics, Faculty of Medicine, Pamukkale University, Denizli, Turkey.
Sci Rep. 2025 Apr 25;15(1):14471. doi: 10.1038/s41598-025-99445-3.
Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders in women of reproductive age. PCOS is associated with many chronic complications such as endometrial thickening, endometrial cancer, breast cancer, infertility, dyslipidemia, and long-term cardiovascular disease. Therefore, many parameters and markers should be used in the evaluation of patients diagnosed with PCOS. Calprotectin has also been shown to be an important marker of destruction in many diseases that progress with inflammatory processes. The objective of our study was to examine the diagnostic efficacy of calprotectin in the context of polycystic ovary syndrome. In this study, 39 patients diagnosed with polycystic ovary syndrome and 41 healthy controls were analyzed. Serum calprotectin levels were compared between patients with different phenotypes of PCOS and a control group. Our study demonstrates significant differences in hormonal and inflammatory parameters between PCOS patients and healthy controls. PCOS patients exhibited significantly lower FSH levels and higher LH levels, resulting in a marked increase in the LH/FSH ratio. Additionally, DHEA-S and total testosterone levels were significantly elevated in the PCOS group, while SHBG levels were notably lower. The free androgen index (FAI) and serum calprotectin levels were also significantly higher in the PCOS group, highlighting the potential role of calprotectin in the pathophysiology of the disorder. Our study demonstrated that serum calprotectin levels are significantly higher in patients with PCOS compared to healthy controls. This finding underscores the potential role of calprotectin in the pathophysiology of PCOS and suggests that this marker could provide valuable insights into the inflammatory processes associated with the condition. However, further large-scale and long-term studies are necessary to better understand the impact of calprotectin on different PCOS phenotypes and its potential application in clinical practice.
多囊卵巢综合征（PCOS）是育龄女性最常见的内分泌疾病之一。PCOS与许多慢性并发症相关，如子宫内膜增厚、子宫内膜癌、乳腺癌、不孕症、血脂异常和长期心血管疾病。因此，在评估诊断为PCOS的患者时应使用许多参数和标志物。钙卫蛋白也已被证明是许多随炎症过程进展的疾病中破坏的重要标志物。我们研究的目的是在多囊卵巢综合征的背景下检查钙卫蛋白的诊断效能。在本研究中，分析了39例诊断为多囊卵巢综合征的患者和41例健康对照。比较了不同PCOS表型患者与对照组之间的血清钙卫蛋白水平。我们的研究表明，PCOS患者与健康对照之间在激素和炎症参数方面存在显著差异。PCOS患者的促卵泡生成素（FSH）水平显著降低，促黄体生成素（LH）水平升高，导致LH/FSH比值显著增加。此外，PCOS组硫酸脱氢表雄酮（DHEA-S）和总睾酮水平显著升高，而性激素结合球蛋白（SHBG）水平显著降低。PCOS组的游离雄激素指数（FAI）和血清钙卫蛋白水平也显著更高，突出了钙卫蛋白在该疾病病理生理学中的潜在作用。我们的研究表明，与健康对照相比，PCOS患者的血清钙卫蛋白水平显著更高。这一发现强调了钙卫蛋白在PCOS病理生理学中的潜在作用，并表明该标志物可为与该疾病相关的炎症过程提供有价值的见解。然而，需要进一步的大规模长期研究，以更好地了解钙卫蛋白对不同PCOS表型的影响及其在临床实践中的潜在应用。
